RECRUITINGOBSERVATIONAL
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
About This Trial
This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.
Who May Be Eligible (Plain English)
Who May Qualify:
- Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
- Receiving asparaginase as part of the primary treatment regimen
- Ability to understand and the willingness to sign a written willing to sign a consent form
- For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
Who Should NOT Join This Trial:
- Patients who are unable to give willing to sign a consent form
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
* Receiving asparaginase as part of the primary treatment regimen
* Ability to understand and the willingness to sign a written informed consent
* For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
Exclusion Criteria:
* Patients who are unable to give informed consent
Treatments Being Tested
PROCEDURE
Biospecimen Collection
Undergo collection of saliva
Locations (1)
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States